Trial Profile

A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary) ; Hydroxychloroquine; Methotrexate; Sulfasalazine
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms SWEFOT

12 Nov 2020 Results comparing mortality risk over fourteen years of follow-up published in the Rheumatology
01 Feb 2019 Results (n=298) of patients from the Swedish Pharmacotherapy (SWEFOT) clinical trial, assessing baseline serum levels of 12 protein for association with disease activity based on the 28-joint count Disease Activity Score (DAS28) after 3 months of MTX monotherapy, published in The Journal of Rheumatology.
16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com